Escitalopram: In the treatment of major depressive disorder in adolescent patients

Pediatric Drugs

Volumn 12, Issue 3, 2010, Pages 155-162

  Yang, Lily P H ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Adolescents; Depressive disorders

Indexed keywords

CARBAMAZEPINE; CIMETIDINE; CITALOPRAM; DESIPRAMINE; DIGOXIN; ESCITALOPRAM; ESERTIA; KETOCONAZOLE; LINEZOLID; LITHIUM; METOPROLOL; OMEPRAZOLE; PIMOZIDE; PLACEBO; RITONAVIR; THEOPHYLLINE; TRAMADOL; TRIAZOLAM; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; WARFARIN;

ABDOMINAL PAIN; ACCIDENTAL INJURY; AREA UNDER THE CURVE; CHILD PSYCHIATRY; CLINICAL TRIAL; COMPETITIVE INHIBITION; DIARRHEA; DISEASE SEVERITY; DRUG BINDING; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HUMAN; HYPERICUM PERFORATUM; INCIDENCE; INDIGESTION; INSOMNIA; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MENSTRUAL CRAMP; MENSTRUATION DISORDER; MENTAL PATIENT; META ANALYSIS; NAUSEA; PHARYNGITIS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RATING SCALE; RECOMMENDED DRUG DOSE; REVIEW; RHINITIS; SINGLE DRUG DOSE; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; THERAPY EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADOLESCENT; ANIMALS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DRUG DOSAGE CALCULATIONS; HUMANS; TREATMENT OUTCOME;

EID: 77952578080     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11204340-000000000-00000     Document Type: Review

References (36)

1. Birmaher B, Brent D, Bernet W, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. AACAP Work Group on Quality Issues. J Am Acad Child Adolesc Psychiatry 2007 Nov; 46 (11): 1503-1526
2. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008 Jan 3; 358 (1): 55-68
3. American Psychiatric Association. Mood disorders. In: Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994: 317-392
4. Adams SM, Miller KE, Zylstra RG. Pharmacologic management of adult depression. Am Fam Physician 2008 Mar 15; 77 (6): 785-792
5. Bylund DB, Reed AL. Childhood and adolescent depression: why do children and adults respond differently to antidepressant drugs? Nuerochem Int 2007 Oct; 51 (5): 246-253
6. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009 Aug 11; 339: b2880
7. Cohen D, Deniau E, Maturana A, et al. Are child and adolescent responses to placebo higher in major depression than in anxiety disorders? A systematic review of placebo-controlled trials. PLoS One 2008 Jul 9; 3 (7): e2632
8. Hetrick S, Merry S, McKenzie J, et al. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2007 Jul 18; (3): CD004851
9. Tsapakis EM, Soldani F, Tondo L, et al. Efficacy of antidepressants in juvenile depression: meta-analysis [published errata appear in Br J Psychiatry 2008 Aug; 193 (2): 169, and 2008 Oct; 193 (4): 346]. Br J Psychiatry 2008 Jul; 193 (1): 10-17
10. Cheung AH, Zuckerbrot RA, Jensen PS, et al. Guidelines for adolescent depression in primary care (GLAD-PC): II. Treatment and ongoing management [published erratum appears in Pediatrics 2008 Jan; 121 (1): 227]. Pediatrics 2007 Nov; 120 (5): e1313-26
11. National Institute for Health and Clinical Excellence. Depression in children and young people: identification and management in primary, community and secondary care (clinical guideline 28) [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/CG028NICEguideline.pdf [Accessed 2010 Mar 10]
12. Forest Laboratories, Inc. Forest Laboratories, Inc. announces FDA approval of Lexapro(R) for the treatment of major depressive disorder in adolescents [online]. Available from URL: http://www.frx.com/news/PressRelease. aspx? ID=1268211 [Accessed 2010 Mar 10]
13. Forest Laboratories, Inc. Lexapro- (escitalopram oxalate) tablets and oral solution: US prescribing information [online]. Available from: http:// www.frx.com/pi/lexapro-pi.pdf [Accessed 2010 Mar 10]
14. Murdoch D, Keam SJ. Escitalopram: a review of its use in the management of major depressive disorder. Drugs 2005; 65 (16): 2379-2404
15. Sánchez C, Bøgesø KP, Ebert B, et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004 Jul; 174 (2): 163-176
16. Kasper S, Sacher J, Klein N, et al. Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. Int Clin Psychopharmacol 2009 May; 24 (3): 119-125
17. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006 Jun 15; 59 (12): 1116-1127
18. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007; 46 (4): 281-290
19. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001 Sep 1; 50 (5): 345-350
20. Chen F, Larsen MB, Sánchez C, et al. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005 Mar; 15 (2): 193-198
21. Mørk A, Kreilgaard M, Sánchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 2003 Aug; 45 (2): 167-173
22. Von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001 Aug; 29 (8): 1102-1109
23. Periclou A, Rao N, Sherman T, et al. Single-dose pharmacokinetic study of escitalopram in adolescents and adults. Pharmacotherapy 2003 Oct 10; 23 (10): 1361-1362
24. Wingen M, Bothmer J, Langer S, et al. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 2005 Apr; 66 (4): 436-443
25. Søgaard B, Mengel H, Rao N, et al. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol 2005 Dec; 45 (12): 1400-1406
26. Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther 2003 Apr; 25 (4): 1200-1210
27. Malling D, Poulsen MN, Søgaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br JClin Pharmacol 2005 Sep; 60 (3): 287-290
28. Cattaneo A, Bocchio-Chiavetto L, Zanardini R, et al. Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. Int J Neuropsychopharmacol 2010 Feb; 13 (1): 103-108
29. Jin Y, Pollock BG, Frank E, et al. Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. J Clin Pharmacol 2010 Jan; 50 (1): 62-72
30. Nadeem HS, Attenburrow M-J, Cowen PJ. Comparison of the effects of citalopram and escitalopram on 5-HT-mediated neuroendocrine responses. Neuropsychopharmacology 2004 Sep; 29 (9): 1699-1703
31. Emslie GJ, Ventura D, Korotzer A, et al. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry 2009 Jul; 48 (7): 721-729
32. Wagner KD, Jonas J, Findling RL, et al.Adouble-blind, randomized, placebocontrolled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 2006 Mar; 45 (3): 280-288
33. Forest Laboratories, Inc. A double-blind, fixed-dose extension study of escitalopram in pediatric patients with major depressive disorder [study no. SCTMD- 32A] [online]. Available from URL: http://www.forestclinicaltrials.com/ CTR/CTRController/CTRViewPdf?-file-id=scsr/SCSR-SCT-MD-23-23A- final.pdf [Accessed 2010 Mar 10]
34. Wagner KD, Robb AS, Findling RL, et al. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 2004 Jun; 161 (6): 1079-1083
35. Von Knorring A-L, Olsson GI, Thomsen PH, et al. A randomized, doubleblind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol 2006 Jun; 26 (3): 311-315
36. Ventura D, Robb A, Bose A, et al. CDRS-R subscale analysis in a randomized placebo-controlled trial of escitalopram in depressed adolescents [abstract no. NR2-073]. 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco (CA)